MRK VS GILD....AND THE WINNER IS

Discussion in 'Merck' started by anonymous, Jan 22, 2016 at 8:09 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    READ THIS GREAT POST.....Hey Mr. Tod Putz from MRK, are you taking something really bad as a sleep aid with dark looming shadows. So here is the bottom line GILD has the best science and outcomes, focused market driven strategy, good people managements, terrific account managers, KOLs love us, market is satisfied and not interested in MRK's 50 to 55% discount. Plus we at GILD are highly motivated, successful and proud of our accomplishments and are moving on to a even better combinations with improved outcomes. Truth be said, Mrk is a badly managed company. So this sums things up for you Mr. Putz. Good luck in Florida hope your launch meeting is not being run by losers responsible for Vioxx, failures in the cholesterol markets, all recent launches and all the other fuck ups in the vaccine div. Good luck and see you in the market and lets go to war and have fun and confirm again that GILD is an outstanding competitor.
     

  2. anonymous

    anonymous Guest

    I am looking forward to watching how bad Merck can screw up their launch. Gilead will eat their lunch. I can't believe they still have the same upper management in place for the hep c/hiv division.
     
  3. anonymous

    anonymous Guest

    Merck management is corrupt and evil so they continue to hire and reward like minded folks. They don't learn from their past so they are doomed to repeat it. Any good leadership at Merck has since left, got fired or have given up and gone into survival mode.
     
  4. anonymous

    anonymous Guest

    Cool Beans!
     
  5. anonymous

    anonymous Guest

    MERCK!!!
     
  6. anonymous

    anonymous Guest

    The WAR has begun. Separate the boys from men. So exciting. Mrk has to prove a lot. Exciting.
     
  7. anonymous

    anonymous Guest

    Our label is a tough sell. We will see.
     
  8. anonymous

    anonymous Guest

    Gilead took a swift kick to the nuts! I love my Merck steel toe boots. :)
     
  9. anonymous

    anonymous Guest

    And then you woke up... We'll let the VPak reps sell negatively against you. Have fun spinning your PI. Sure looks like you are going back to "response guided therapy" with that dosing, resistance profile and lab monitoring. Yikes!!!
     
  10. anonymous

    anonymous Guest

    That drug is no doubt a dog. It's actually funny. It needs a third agent because the protease sucks. It's so bad you came in at cheap price. VP is. Better option. Welcome to HCV where Gilead rules the land and will fight to death. You rebate we rebate bitches. Take a good look at abbvie. Because that's where you'll be in a year.
     
  11. anonymous

    anonymous Guest

    Hey poster....you are right the label sucks and that is why the product is discounted and that is exactly why very sneaky mrk is discounting it and making it an access issue. So smart marketing to reset these negative label. Adam says...."Lets wait and see what the FDA label says" MRK already know and is obviously is not being truthful. So what else is new from the makers of Vioxx and bullshit science of Niacin.

    "One more reason could be behind Zepatier's lower price, not mentioned by Merck: The drug may not be as effective or convenient as Gilead's Harvoni. The FDA label for Zepatier recommends doctors screen genotype 1a hepatitis C patients for mutations in the virus, which if present, lower the drug's cure rate. This genetic testing is not routinely done for hepatitis C patients today and is not included in the Harvoni or Viekira Pak labels.

    The Zapatier label also recommends doctors test patients treated for elevated liver enzyme levels, a potential negative side effect. Viekira Pak's label also includes a recommendation for liver monitoring but Harvoni's does not".
     
  12. anonymous

    anonymous Guest

    http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf
     
  13. anonymous

    anonymous Guest

    Is Bob/Rob "The Used Car Salesman" Lazo still selling HCV? What a f&@?ing joke of an asswipe.
     
  14. anonymous

    anonymous Guest

    We need revenue growth badly to stop the stock from dropping further. So this was a great move.
    Good job Ken.
     
  15. anonymous

    anonymous Guest

    We don't care about margins at this time. What matter's more in booking the sales.
    Our revenue line must grow.
     
  16. anonymous

    anonymous Guest

    Don't go dissing Hyundai Bob, he is the last of a dying breed of old school reps who doesn't think about pissing off a doctor by running them down in the parking lot just to say he had an interaction with them......
     
  17. anonymous

    anonymous Guest

    Merck doesn't have a prayer. A distant second-place finisher…

    The sales force will get smaller in every group before year's end.
     
  18. anonymous

    anonymous Guest

    Something Accounting Bob would say. Such a weak person. Does he still wear his gold bracelet to be cool.
     
  19. anonymous

    anonymous Guest

    see u all at the cheap ass launch meeting
     
  20. anonymous

    anonymous Guest

    The CV group is first on the block. Heads up!